Suppr超能文献

夜间血液透析与常规血液透析对终末期肾病的影响:一项Meta分析和系统评价

Effect of Nocturnal Hemodialysis versus Conventional Hemodialysis on End-Stage Renal Disease: A Meta-Analysis and Systematic Review.

作者信息

Liu Fangjie, Sun Yiting, Xu Tianhua, Sun Li, Liu Linlin, Sun Wei, Feng Xin, Ma Jianfei, Wang Lining, Yao Li

机构信息

Department of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.

Department of Clinical Medicine, China Medical University, Shenyang, Liaoning, China.

出版信息

PLoS One. 2017 Jan 20;12(1):e0169203. doi: 10.1371/journal.pone.0169203. eCollection 2017.

Abstract

OBJECTIVES

The purpose of this study is to assess the efficacy and safety of nocturnal hemodialysis on end-stage renal disease (ESRD) patients.

METHODS

We searched Medline, EmBase, and the Cochrance Central Register of Controlled Trials for studies up to January 2016. Analysis was done to compare variant outcomes of different hemodialysis schedules, including mortality, cardiovascular-associated variables, uremia-associated variables, quality of life (QOL), side-effects, and drug usage.

RESULTS

We collected and analyzed the results of 28 studies involving 22,508 patients in our meta-analysis. The mortality results in this meta-analysis indicated that the nocturnal hemodialysis (NHD) group was not significantly different from conventional hemodialysis (CHD) group (Mortality: OR: 0.75; 95% confidence intervals (CIs): 0.52 to 1.10; p = 0.145), but the CHD group had significantly fewer number of hospitalizations than the NHD group (OR: 1.54; 95%CI: 1.32 to 1.79; p<0.001). NHD was superior to CHD for cardiovascular-associated (left ventricular hypertrophy [LVH]: SMD: -0.39; 95%CI: -0.68 to -0.10; p = 0.009, left ventricular hypertrophy index [LVHI]: SMD: -0.64; 95%CI: -0.83 to -0.46; p<0.001) and uremia-associated intervention results (Serum albumin: SMD: 0.89; 95%CI: 0.41 to 1.36; p<0.001). For the assessment of quality of life, NHD treatment significantly improved the patients' QOL only for SF36-Physical Components Summary (SMD: 0.43; 95%CI: 0.26 to 0.60; p<0.001). NHD intervention was relatively better than CHD for anti-hypertensive drug usage (SMD: -0.48; 95%CI: -0.91 to -0.05; p = 0.005), and there was no difference between groups in our side-effects assessment.

CONCLUSION

NHD and CHD performed similarly in terms of ESRD patients' mortality and side-effects. NHD was superior to CHD for cardiovascular-associated and uremia-associated results, QOL, and drug usage; for number of hospitalizations, CHD was relatively better than NHD.

摘要

目的

本研究旨在评估夜间血液透析对终末期肾病(ESRD)患者的疗效和安全性。

方法

我们检索了截至2016年1月的Medline、EmBase和Cochrance对照试验中央注册库中的研究。进行分析以比较不同血液透析方案的不同结果,包括死亡率、心血管相关变量、尿毒症相关变量、生活质量(QOL)、副作用和药物使用情况。

结果

我们在荟萃分析中收集并分析了28项研究的结果,涉及22508名患者。该荟萃分析中的死亡率结果表明,夜间血液透析(NHD)组与传统血液透析(CHD)组无显著差异(死亡率:OR:0.75;95%置信区间(CI):0.52至1.10;p = 0.145),但CHD组的住院次数明显少于NHD组(OR:1.54;95%CI:1.32至1.79;p<0.001)。在心血管相关(左心室肥厚[LVH]:标准化均值差[SMD]:-0.39;95%CI:-0.68至-0.10;p = 0.009,左心室肥厚指数[LVHI]:SMD:-0.64;95%CI:-0.83至-0.46;p<0.001)和尿毒症相关干预结果方面,NHD优于CHD(血清白蛋白:SMD:0.89;95%CI:0.41至1.36;p<0.001)。对于生活质量评估,NHD治疗仅在SF36身体成分总结方面显著改善了患者的QOL(SMD:0.43;95%CI:0.26至0.60;p<0.001)。在抗高血压药物使用方面,NHD干预相对优于CHD(SMD:-0.48;95%CI:-0.91至-0.05;p = 0.005),且在副作用评估中两组之间无差异。

结论

在ESRD患者的死亡率和副作用方面,NHD和CHD表现相似。在心血管相关和尿毒症相关结果、QOL和药物使用方面,NHD优于CHD;在住院次数方面,CHD相对优于NHD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e16f/5249197/b487fa4c8133/pone.0169203.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验